The Predictive Role of Inflammatory Biomarkers for Treatment Response and Progression-Free Survival in Patients with Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy with FOLFOX Regimen: A Preliminary Study

作者：Yang Zhao, Jun Liu, Zhengping Xiong, S Gu, Xibin Xia · 发表于：Journal of Hepatocellular Carcinoma · 年份：2023 · DOI：10.2147/jhc.s413283 · 被引用次数：10 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Hepatocellular Carcinoma Treatment and Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies

Objective: This retrospective study aimed to investigate whether pre-treatment inflammatory biomarkers, including the prognostic nutritional index (PNI), monocyte-lymphocyte ratio (MLR), systemic immune inflammation index (SII), and platelet-lymphocyte ratio (PLR), could predict treatment response and prognosis in patients with hepatocellular carcinoma (HCC) receiving hepatic arterial infusion chemotherapy (HAIC) with the oxaliplatin, leucovorin, and fluorouracil (FOLFOX) regimen. Methods: Based on the cut-off values identified using the receiver-operating characteristic (ROC) curve, 124 patients with HCC who received HAIC with the FOLFOX regimen were divided into low- and high-score MLR, PLR, PNI, and SII groups. Univariate and multivariate regression analyses were performed to identify independent predictors of treatment response and progression-free survival (PFS). Results: The cut-off values were 0.569 for MLR (area under the curve [AUC]: 0.621), 177.01 for PLR (AUC: 0.554), 713.05 for SII (AUC: 0.570), and 46.85 for PNI (AUC: 0.665). Multivariate Cox regression analysis revealed that the modified albumin-bilirubin (mALBI) grade (hazard ratio [HR]: 2.027; P =0.032), high MLR (HR: 7.250; P =0.002), and low PNI (HR: 0.296; P =0.003) were independent predictors of HAIC non-response, with an AUC value of 0.746 (95% CI: 0.658– 0.833). A high MLR (HR: 1.714, 95% CI: 1.086– 2.704, P =0.021) was also an independent predictor of PFS. Kaplan–Meier analysis showed that the patients ...